Will Guidant Return To Pharma Roots After 10 Years As Stand-Alone Entity?
This article was originally published in The Gray Sheet
Executive Summary
Guidant's cardiac surgery device and guiding catheter segments offer an attractive fit with Johnson & Johnson, though ICD market access and drug-eluting stent synergies would be the true drivers of any merger
You may also be interested in...
J&J Claims Guidant For $23.9 Bil., Forms CV Device Group Under Valeriani
Johnson & Johnson's willingness to pay $24 bil. (6.5-times revenue) for Guidant validates the long-standing claim of ICD manufacturers that the cardiac rhythm management market is largely underserved
Bard To Join Carotid Stent Fray In 2005 With IDE Trial
Bard's decision to enter the carotid stent race in 2005 reflects the firm's confidence that it will become a top player in the emerging field
J&J Claims Guidant For $23.9 Bil., Forms CV Device Group Under Valeriani
Johnson & Johnson's willingness to pay $24 bil. (6.5-times revenue) for Guidant validates the long-standing claim of ICD manufacturers that the cardiac rhythm management market is largely underserved